与「kidneycancer」相关的搜索结果

New in @NEJM: Phase 3 LITESPARK-022 showed belzutifan + pembrolizumab significantly improved disease-free survival in high-risk kidney cancer after surgery. The FDA recently approved the combo in this patient population. Study lead @DrChoueiri of @DanaFarber explains:

Next-generation HIF-2α inhibitor casdatifan shows promising signs of on-target efficacy in first-in-patient clinical trial in metastatic clear cell kidney cancer. Now published in @Nature and led by @DrChoueiri. @DanaFarber_GU ➡️